Comparison of female sexual function and sexual function of their partners between groups of pregnant and non-pregnant women

Objectives: To compare the female sexual function index and sexual function of their partners between groups of pregnantand non-pregnant Turkish women.Material and methods: This was a cross-sectional study of 321 women, including 252 healthy pregnant and 69 healthynonpregnant women. Assessment of female sexual function index (FSFI), ARIZONA scores of their partners were comparedin relation to some of the sociodemographic characteristics and pregnancy trimesters.Results: Comparison of the groups revealed a significantly higher FSFI score in the non-pregnant group whereas the ARIZONAscore was significantly higher in the pregnant group (p < 0.001). Age, gravidity, parity and smoking rate adjustedmean differences of scores remained statistically significant (p < 0.001). Higher ARIZONA (> 11) score rate was significantlyhigher in pregnant groups (55.6% vs 23.2%, p < 0.001). Pregnancy was a risk factor for high ARIZONA score [OR: 4.1 (95%CI 2.2–7.6, p < 0.001)]. Lower FSFI score rate was significantly higher in the pregnant group (26.4% vs 69.4%, p < 0.001).Pregnancy was a risk factor for low FSFI score [OR: 6.4 (95% CI 3.5–11.7, p < 0.001)].Conclusions: Both female sexual function index and ARIZONA scores of their partners were found to be significantly differentbetween groups of pregnant and nonpregnant Turkish women which indicated altered sexual function of couplesduring pregnancy

Tip 2 Diyabetik Erkeklerde Klinik ve Biyokimyasal Olarak Hipogonadizmin Değerlendirilmesi

Tip 2 Diyabetik Erkeklerde Klinik ve Biyokimyasal Olarak Hipogonadizmin DeğerlendirilmesiBuket TEKİN VATANSEVER&nbsp;[1]&nbsp;,&nbsp;&nbsp;Sakin TEKİN&nbsp;[2]&nbsp;,&nbsp;&nbsp;Şule TEMİZKAN&nbsp;[3]&nbsp;,&nbsp;&nbsp;Tülay KARABAYRAKTAR&nbsp;[4]&nbsp;,&nbsp;&nbsp;Berfu ÇINKIT&nbsp;[5]&nbsp;,&nbsp;&nbsp;Asuman ORÇUN&nbsp;[6]&nbsp;,&nbsp;&nbsp;Mustafa TEKÇE&nbsp;[7]&nbsp;,&nbsp;&nbsp;Mehmet USTAOĞLU&nbsp;[8]&nbsp;,&nbsp;&nbsp;Mehmet SARGIN&nbsp;[9]&nbsp;703&nbsp;&nbsp;2.126https://doi.org/10.17098/amj.80992ÖzentrGiriş:&nbsp;Erkeklerde hipogonadizm, serum androjen seviyelerindeki azalma ile karakterize klinik ve biyokimyasal bir durumdur. Diyabetik erkeklerde diyabetik olmayanlara göre testosteron düzeylerinin daha düşük olduğu çalışmalarda gösterilmiştir. Biz de bu çalışmamızda diyabetik erkeklerde ve yaş uyumlu kontrol grubunda klinik ve laboratuvar olarak saptanmış hipogonadizmin sıklığını karşılaştırmayı amaçladık.Materyal ve Metot:&nbsp;Çalışmaya 1– 15 Temmuz 2012 tarihleri arasında Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi Diyabet Polikliniğine başvuran ardışık 65 DM tip 2 hastası alındı. Kontrol grubuna, çalışma grubuyla yaşları benzer, diyabeti olmayan 40 erkek alındı. Tüm katılımcıların, antropometrik ölçümleri, biyokimyasal ve hormonal tetkikleri değerlendirmeye alındı. Bioavailable ve serbest testosteron değeri hesaplaması ‘International Society For The Study of The Aging Male’in resmi sitesindeki (www.issam.ch) otomatik hesaplama ekranından, total testosteron, seks hormon bağlayıcı globulin (SHBG) ve albumin değerleri kullanılarak yapıldı.Bulgular:&nbsp;Diyabetik hastaların ve kontrol grubunun yaş ortalamaları sırasıyla 52,2 ± 5,0 ve 50,8 ± 6,0 yıl, beden kitle indeksi ortalamaları 27,8±2,9 ve 27,9±3,9 kg/m2&nbsp;ve bel çevresi ortalamaları 100,8±7,3 ve 97,9±17,5 cm olarak tespit edildi. Diyabetik grupta kontrol grubuyla kıyaslandığında total testosteron ve SHBG düzeylerinin istatistiksel olarak anlamlı daha düşük olduğu saptandı (sırasıyla p= 0,005 ve p= 0,02., Diyabetik hastalarda, total testosteron düzeylerine göre, %8,2 hastada belirgin hipogonadizm, % 29,5 hastada sınırda hipogonadizm, kontrol grubunda ise % 5,7 hastada belirgin hipogonadizm, % 20 hastada sınırda hipogonadizm tespit edildi, İki grup arasında istatistiksel anlamlı fark saptanmadı. Diyabetik grupta Aging Male Symptoms Sorgulama Formu (AMS-SF) skorlarına göre hipogonadizm semptomları değerlendirildiğinde % 11 ciddi semptomatik, % 30,2 orta semptomatik, % 34,9 düşük semptomatik olduğu saptandı, Kontrol grubunda AMS-SF skorlarına göre hipogonadizm semptomları değerlendirildiğinde % 2,5 ciddi semptomatik, % 15 orta semptomatik, % 47,5 düşük semptomatik olduğu saptandı. Diyabetik grup ile kontrol grubu arasında hipogonadizm semptomlarının şiddeti açısından istatistiksel anlamlı bir fark saptandı. Diyabetik grupta antropometrik ölçümlerden bel çevresi ve beden kitle indeksi (BKİ) ile, kontrol grubunda ise bel çevresi ile total testosteron ve bioavailable testosterone arasında negatif korelasyon saptandı.Sonuç:&nbsp;Tip 2 diyabetik erkeklerde kontrol grubuyla kıyaslandığında total testosteron düzeyi düşük saptanmasına rağmen biyokimyasal hipogonadizm sıklığında artış saptanmadı. Bununla birlikte klinik açıdan ciddi ve orta semptomatik hipogonadizm sıklığında artış olduğu gösterilmiştir, Ayrıca diyabetik hastalarda bel çevresi ve BKİ değerleri ile ve kontrol grubunda sadece bel çevresi ile total testosteron düzeylerinin negatif ilişkili olduğu gösterilmiştir.Anahtar KelimelerentrClinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes MellitusBuket TEKİN VATANSEVER&nbsp;[1]&nbsp;,&nbsp;&nbsp;Sakin TEKİN&nbsp;[2]&nbsp;,&nbsp;&nbsp;Şule TEMİZKAN&nbsp;[3]&nbsp;,&nbsp;&nbsp;Tülay KARABAYRAKTAR&nbsp;[4]&nbsp;,&nbsp;&nbsp;Berfu ÇINKIT&nbsp;[5]&nbsp;,&nbsp;&nbsp;Asuman ORÇUN&nbsp;[6]&nbsp;,&nbsp;&nbsp;Mustafa TEKÇE&nbsp;[7]&nbsp;,&nbsp;&nbsp;Mehmet USTAOĞLU&nbsp;[8]&nbsp;,&nbsp;&nbsp;Mehmet SARGIN&nbsp;[9]&nbsp;703&nbsp;&nbsp;2.126https://doi.org/10.17098/amj.80992ÖzentrObjectives: Hypogonadism is a clinical condition comprising both symptoms and biochemical evidence of testosterone deficiency. It has been reported that testosterone levels are lower in diabetic men compared with nondiabetic subjects. The aim of our study was to assess the prevalence of&nbsp; hypogonadism, based on both symptoms and biochemically available measures of testosterone deficiency in men with type 2 diabetes mellitus (DM) and to compare with control group.Materials and Methods:&nbsp;A cross sectional study was carried out in type 2 patients who attended the outpatient clinic of Diabetes Kartal Training and Research hospital. Between the 1th July and 15th July 2012, 65 consecutive patients were included to the study. Control group is created by age matched 40 non diabetic patients. Blood pressure, waist circumference, height, weight and testosterone levels were measured. Body mass index (BMI) was calculated. Bioavailable testosterone and free testosterone levels were calculated on the internet (http://www.issam.ch/www.androloji.org.tr) by using the levels of albumin, total testosterone and sex hormone binding protein.Results:&nbsp;Diabetic patients and control group’s mean age was respectively 52.2±5.0 and 50.8±6.0 year, mean BMI 27.8±2.9 and 27.9±3.9 kg/m2and mean waist circumference 100.8±7.3 and 97.9±17.5 cm. Men with type 2 diabetes had significantly lower total testosterone and SGBH than control group (respectively p= 0,005 ve p= 0,02). According to total testosterone levels, overt hypogonadism was seen in 8.2% of diabetic patients, borderline hypogonadism was seen in&nbsp; 29.5 % of diabetic patients. In control group overt hypogonadism was seen in 5.7 %, borderline hypogonadism was seen in 20 % of control group. According to chemical hypogonadism based on total, bioavailable and calculated testosterone levels, there were no statistically difference between groups. In diabetic group, 11 % severe, 30.2 % moderate, 34.9 % mild complaints were recorded according to AMS results. In control group, 2.5 % severe, 15 % moderate, 47.5 % mild complaints were recorded according to AMS results. Men with type 2 diabetes had significantly higher severe and moderate complaints of hypogonadism than control group. In diabetic group waist circumference, BMI and in control group waist circumference were negatively correlated with testosterone levels.Conclusion:&nbsp;This study demonstrates that men with type 2 DM had significantly lower total testosterone but not significantly higher biochemical hypogonadism than control group. At the same time, men with type 2 DM had significantly higher severe and moderate complaints of&nbsp; hypogonadism than control group. In diabetic group waist circumference, BMI and in control group waist circumference were associated with low testosterone levels.&nbsp;Anahtar KelimelerentrClinical and biochemical hypogonadism,&nbsp;men with type 2 DM</div

Comparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities

Aim: Study aims to assess amylase, lipase of patients with Type 2 diabetes under different types of treatments. Materials & methods: Patients' treatment modalities including insulin, metformin, pioglitazone, sodium-glucose co-transporter-2 inhibitors, insulin secretagogues, dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists were compared. Results: There was no difference in amylase and lipase levels between dipeptidyl peptidase-4 inhibitor users and non-users (p = 0.2, p = 0.3, respectively) and glucagon like peptide-1 analog users and non-users (p = 0.1, p = 0.7, respectively). Patients who use insulin secretagogues had significantly higher amylase, lipase and (77.2 +/- 39.8 vs 69.5 +/- 33.0, p = 0,038 and 47.2 +/- 33.2 vs 39.6 +/- 26.8, p = 0.01, respectively) patients on basal insulin had lower amylase levels (69.9 +/- 37.7 vs 77.2 +/- 33.7, p = 0.014). Conclusion: Incretin-based therapies showed no difference in amylase and lipase levels whereas there was increase with secretagogues and decrease with basal insulin

Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas

Purpose To assess baseline T2-weighted signal intensity (T2-WSI) of functional pituitary adenomas (FPA), and to investigate the relationship of baseline T2-WSI with clinical features, histopathological granulation patterns, and response to treatment in patients with acromegaly, prolactinoma and Cushing's disease (CD)